| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CG-3 |
| Uniprot No | P0DO16 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 194-605aa |
| 氨基酸序列 | NPFLFGSNRFETLFKNQYGRIRVLQRFNQRSPQLQNLRDYRILEFNSKPNTLLLPNHADADYLIVILNGTAILSLVNNDDRDSYRLQSGDALRVPSGTTYYVVNPDNNENLRLITLAIPVNKPGRFESFFLSSTEAQQSYLQGFSRNILEASYDTKFEEINKVLFSREEGQQQGEQRLQESVIVEISKEQIRALSKRAKSSSRKTISSEDKPFNLRSRDPIYSNKLGKFFEITPEKNPQLRDLDIFLSIVDMNEGALLLPHFNSKAIVILVINEGDANIELVGLKEQQQEQQQEEQPLEVRKYRAELSEQDIFVIPAGYPVVVNATSNLNFFAIGINAENNQRNFLAGSQDNVISQIPSQVQELAFPGSAQAVEKLLKNQRESYFVDAQPKKKEEGNKGRKGPLSSILRAFY |
| 预测分子量 | 54.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于CG-3重组蛋白的虚构参考文献示例，格式符合学术规范，供参考：
---
1. **标题**: "Efficient Expression and Purification of CG-3 Recombinant Protein in *E. coli* for Functional Studies"
**作者**: Zhang, L., Wang, Y., & Chen, H.
**摘要**: 本研究构建了CG-3基因的原核表达载体，优化了其在大肠杆菌中的诱导表达条件，并通过镍柱亲和层析实现了高纯度CG-3重组蛋白的制备。实验表明，纯化的CG-3蛋白在体外具有显著的抗氧化活性，为后续机制研究奠定了基础。
2. **标题**: "Structural Characterization of CG-3 Recombinant Protein and Its Role in Cell Proliferation"
**作者**: Kim, S., Tanaka, M., & Patel, R.
**摘要**: 通过X射线晶体学解析了CG-3重组蛋白的三维结构，发现其具有独特的α-螺旋结构域。体外细胞实验显示，CG-3可促进成纤维细胞增殖，并激活MAPK信号通路，提示其在组织修复中的潜在应用价值。
3. **标题**: "CG-3 Recombinant Protein Attenuates Inflammatory Response in Murine Sepsis Model"
**作者**: González, A., Müller, P., & Li, X.
**摘要**: 在小鼠脓毒症模型中，腹腔注射CG-3重组蛋白显著降低了血清TNF-α和IL-6水平，并减轻了肺组织病理损伤。结果表明CG-3可能通过抑制NF-κB通路发挥抗炎作用，为治疗炎症性疾病提供了新思路。
4. **标题**: "Development of a CG-3-Based ELISA Kit for Early Diagnosis of Neurodegenerative Diseases"
**作者**: Smith, J., Okafor, C., & Gupta, R.
**摘要**: 研究利用CG-3重组蛋白作为抗原，开发了高灵敏度的双抗体夹心ELISA检测方法。临床样本验证显示，该方法可特异性识别阿尔茨海默病患者脑脊液中的CG-3异常聚集，具有诊断潜力。
---
**注**：以上文献为模拟内容，实际研究中若需引用请核实真实文献。建议通过PubMed或Web of Science以“CG-3 protein”“recombinant CG-3”等关键词检索最新成果。
CG-3 recombinant protein is a synthetic biomolecule engineered for applications in biomedical research and therapeutic development. Derived from advanced genetic engineering techniques, CG-3 is typically designed to mimic or enhance specific functional properties of naturally occurring proteins. Its development is rooted in the growing demand for targeted therapies, particularly in oncology, immunology, and regenerative medicine. Researchers often utilize recombinant proteins like CG-3 due to their high purity, consistency, and scalability compared to proteins isolated from natural sources.
The structural design of CG-3 often incorporates domains optimized for binding to cellular receptors or signaling molecules, enabling precise modulation of biological pathways. For instance, it may feature fusion domains combining a receptor-targeting moiety with a functional effector component (e.g., cytokine or enzyme) to achieve dual therapeutic effects. Such engineering allows CG-3 to interfere with disease mechanisms, such as inhibiting tumor growth by blocking angiogenesis or regulating immune responses through checkpoint modulation.
Production typically involves expression systems like mammalian cell cultures (e.g., CHO cells) or microbial platforms (e.g., E. coli), depending on post-translational modification requirements. Rigorous purification processes ensure minimal endotoxin contamination and batch-to-batch reproducibility. CG-3’s preclinical applications include in vitro assays to study protein-protein interactions and in vivo models to evaluate pharmacokinetics and toxicity profiles. Emerging studies also explore its potential in drug delivery systems or as a diagnostic biomarker. Challenges remain in optimizing stability, bioavailability, and cost-effectiveness for clinical translation, but CG-3 exemplifies the convergence of protein engineering and precision medicine.
×
